Midterm Results of Surgical Intramyocardial Implantation of Autologous Angiogenic Cell Precursors for Cardiomyopathy

Main Article Content

Permyos Ruengsakulrach, MD, PhD
Vitoon Pitiguagool, MD
Piyapan Pamornsing, MD
Kosin Thupvong, MD


To report midterm results and assess clinical markers which can predict intramyocardial angiogenic cell precursors (ACPs) injection for cardiomyopathy outcomes.
Between May 2005 and April 2010, 143 consecutive cardiomyopathy patients underwent intramyocardial ACPs injection. Sixty patients were dilated cardiomyopathy (DCM) and 83 were ischemic cardiomyopathy (ICM). Mean age was 59.6 ± 12.1 years. ACPs were isolated from patient’s own blood and cultured. Number of cells prior to injection was 47.3 ± 36.8 million cells. ACPs were injected into non-viable myocardium and hypokinetic segments. Combined coronary artery surgery and cell injection were performed in 34.9% of ICM. Kaplan-Meier was used to estimate survival time. Cox proportional hazard model was applied by fitting data which included age, gender, diagnosis, diabetes, hypertension, hypercholesterolemia, pulmonary hypertension, renal failure, NYHA class, serum creatinine, preop LVEF, type of operations and number of ACPs into the model to identify predictors of death.
There was no new ventricular arrhythmia. Thirty-day mortality rate was 3.3% (2/60) for DCM and 8.4% (7/83) for ICM. Overall death rate was 14.5/1000/month (95%CI: 10.6-19.5). Overall survival probability at 12, 24, 36 and 48 months was 79.9% (95%CI: 72.1-85.8), 67.9% (95%CI: 58.5-75.6), 62.9% (95%CI: 52.4-71.7), 55.4% (95%CI: 43.0-66.2), respectively. LVEF improved by 3.6±12.3% (P=0.04) for DCM and 7.6±10.1% (P<0.001) for ICM. ICM patients with combined coronary artery surgery and cell injection showed more LVEF improvement. (11.8±11.6% vs 4.9±8.0%, P=0.007). Cox regression analyses suggested only preop LVEF (hazard ratio 0.91, 95% CI 0.87-0.95, P<0.001) was associated with decreased survival.
Intramyocardial ACPs injection improved LVEF in both DCM and ICM. Preop LVEF was a significant survival predictor


Download data is not yet available.

Article Details

How to Cite
Ruengsakulrach P, Pitiguagool V, Pamornsing P, Thupvong K. Midterm Results of Surgical Intramyocardial Implantation of Autologous Angiogenic Cell Precursors for Cardiomyopathy. BKK Med J [Internet]. 2017 Feb. 20 [cited 2023 Nov. 30];13(1):21. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/221775
Original Article


1. Wexler RK, Elton T, Pleister A, Feldman D. Cardiomyopathy: an overview. Am Fam Physician 2009;79:778-84.
2. Hellermann JP, Jacobsen SJ, Redfeld MM, et al. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Fail 2005;7:119-25.
3. Menasche P, Alferi O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: frst randomized placebo-controlled study of myoblast transplantation.Circulation 2008;117:1189-200.
4. Hagege AA, Marolleau JP, Vilquin JT, et al. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the frst phase I cohort of patients.Circulation 2006;114:I108-13
5. Porat Y, Porozov S, Belkin D, et al. Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages.Br J Haematol 2006;135:703-14.
6. Sun Z, Wu J, Fujii H, et al. Human angiogenic cell precursors restore function in the infarcted rat heart: a comparison of cell delivery routes.Eur J Heart Fail 2008;10:525-33.
7. Arom KV, Ruengsakulrach P, Jotisakulratana V. Intramyocardial angiogenic cell precursor injection for cardiomyopathy.
Asian Cardiovasc Thorac Ann 2008;16:143-8.
8. Ermis C, Zadeii G, Zhu AX, et al. Improved survival of cardiac transplantation candidates with implantable cardioverter defbrillator therapy: role of beta-blocker or amiodarone treatment. J Cardiovasc Electrophysiol 2003;14:578-83.
9. Williams JA, Patel ND, Nwakanma LU, et al. Outcomes following surgical ventricular restoration in elderly patients with congestive heart failure.Am J Geriatr Cardiol2007;16:67-75.
10. Shuhaiber J, Hur K, Gibbons R. Does the type of ventricular assisted device influence survival, infection, and rejection rates following heart transplantation?J Card Surg 2009;24:250-5.
11. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010;122:173-83.
12. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.Mol Cell Endocrinol 2004;217:53-8.
13. Ather S, Peterson LE, Divakaran VG, et al. Digoxin treatment in heart failure - Unveiling risk by cluster analysis of DIG data.Int J Cardiol 2011;150:264-9.
14. Thekkudan J, Rogers CA, Thomas HL, et al. Trends in adult heart transplantation: a national survey from the United Kingdom Cardiothoracic Transplant Audit 1995-2007.Eur J Cardiothorac Surg 2010;37:80-6.
15. Marelli D, Kobashigawa J, Hamilton MA, et al. Long-term outcomes of heart transplantation in older recipients. J Heart Lung Transplant 2008;27:830-4.
16. Vrtovec B, Poglajen G, Sever M, et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy.J Card Fail 2011;17:272-81.
17. Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: fnal one-year results of the TOPCAREAMI Trial.J Am Coll Cardiol 2004;44:1690-9.
18. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial.Eur Heart J 2009;30:2978-84.
19. Stamm C, Kleine HD, Choi YH, et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and effcacy studies.J Thorac Cardiovasc Surg 2007;133:717-25.
20. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrowderived cells for cardiac repair: a systematic review and meta- nalysis.Arch Intern Med 2007;167:989-97.
21. Assmus B, Rolf A, Erbs S, et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction.Circ Heart Fail 2010;3:89-96.
22. Akar AR, Durdu S, Arat M, et al. Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopathy. Eur J Cardiothorac Surg 2009;36:633-43.
23. Yousef M, Schannwell CM, Kostering M, et al. The BALANCE Study: clinical beneft and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009;53:2262-9.
24. Arom K, Ruengsakulrach P, Jotisakulratana V. Effcacy of Intramyocardial Injection of Angiogenic Cell Precursors for Ischemic Cardiomyopathy: A Case Match Study.Innovations 2008;3:38-45. 25. Arom KV, Ruengsakulrach P, Belkin M, et al. Intramyocardial angiogenic cell precursors in nonischemic dilated cardiomyopathy.Asian Cardiovasc Thorac Ann 2009;17:382-8.